Benchmark analyst maintained a Hold rating on shares of Neogenomics (NASDAQ: NEO). The analysis comes ahead of the company's investor conference presentation scheduled for the same day. The company, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback